Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Invivyd Inc (IVVD)

Invivyd Inc (IVVD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,325
  • Shares Outstanding, K 119,221
  • Annual Sales, $ 0 K
  • Annual Income, $ -198,640 K
  • 60-Month Beta 0.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.28
Trade IVVD with:

Options Overview Details

View History
  • Implied Volatility 351.99% ( +221.83%)
  • Historical Volatility 159.84%
  • IV Percentile 97%
  • IV Rank 49.80%
  • IV High 692.61% on 04/19/24
  • IV Low 14.09% on 06/26/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 9,845
  • Open Int (30-Day) 10,290

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.50
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -0.57
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -56.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +7.50%
on 04/25/24
4.74 -54.64%
on 04/01/24
-1.51 (-41.26%)
since 03/26/24
3-Month
2.00 +7.50%
on 04/25/24
5.20 -58.61%
on 01/31/24
-2.36 (-52.33%)
since 01/26/24
52-Week
0.98 +119.34%
on 06/23/23
5.20 -58.61%
on 01/31/24
+1.06 (+97.25%)
since 04/26/23

Most Recent Stories

More News
Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy?

The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.

IVVD : 2.15 (+3.86%)
PFE : 25.40 (+0.55%)
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?

Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.

HROW : 10.53 (+5.30%)
IKNA : 1.3000 (-0.76%)
SRZN : 8.98 (+4.30%)
IVVD : 2.15 (+3.86%)
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

CTLT : 55.92 (+0.22%)
IKNA : 1.3000 (-0.76%)
SRZN : 8.98 (+4.30%)
IVVD : 2.15 (+3.86%)
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

PKI : 115.24 (-0.91%)
IKNA : 1.3000 (-0.76%)
SRZN : 8.98 (+4.30%)
IVVD : 2.15 (+3.86%)
After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)

Invivyd, Inc. (IVVD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates...

IVVD : 2.15 (+3.86%)
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (IVVD) Investors of Class Action and Last Few Hours to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Invivyd” or the “Company”)...

IVVD : 2.15 (+3.86%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. - IVVD; ADGI

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) ("Adagio" or the "Company")...

IVVD : 2.15 (+3.86%)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Invivyd Investors of a Lead Plaintiff Deadline of April 3, 2023

/PRNewswire/ -- Attention Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. ("Invivyd") (NASDAQ: IVVD) shareholders: The Law Offices of Vincent Wong announce that...

IVVD : 2.15 (+3.86%)
INVIVYD DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Invivyd, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Invivyd, Inc. (“Invivyd” or the “Company”)...

IVVD : 2.15 (+3.86%)
INVIVYD 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications...

IVVD : 2.15 (+3.86%)
ADGI : 4.64 (+0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

INVIVYD INC. is a biopharmaceutical company. It involved in developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. INVIVYD INC., formerly known as Adagio Therapeutics, is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 2.40
2nd Resistance Point 2.32
1st Resistance Point 2.23
Last Price 2.15
1st Support Level 2.06
2nd Support Level 1.98
3rd Support Level 1.89

See More

52-Week High 5.20
Fibonacci 61.8% 3.58
Fibonacci 50% 3.09
Fibonacci 38.2% 2.59
Last Price 2.15
52-Week Low 0.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar